Cabozantinib Versus Standard-of-Care Comparators in the Treatment of Advanced/Metastatic Renal Cell Carcinoma in Treatment-naive Patients: a Systematic Review and Network Meta-Analysis.

ABSTRACT:

Background

Cabozantinib has recently been evaluated as a first-line treatment in advanced renal cell carcinoma (aRCC).

Objective

To indirectly assess efficacy of cabozantinib versus standard-of-care (SoC) comparators in the first-line treatment of aRCC.

Methods

We conducted a systematic literature review (SLR) to identify randomized controlled studies in the first-line setting for aRCC. The outcomes analyzed were overall survival (OS) and progression-free survival (PFS). A network meta-analysis (NMA) was conducted comparing OS and PFS hazard ratios (HRs).

Results

Thirteen studies were identified in the SLR to be eligible for inclusion in the NMA. The overall study populations were heterogeneous in terms of risk groups; some studies included favorable risk patie

SUBMITTER: Schmidt E 

PROVIDER: S-EPMC5887000 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature